Use of bevacizumab in metastatic colorectal cancer: Report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009)

Drugs in R and D

Volumn 11, Issue 2, 2011, Pages 101-111

  Zinser Sierra, Juan W ^a   Rodríguez Ramírez, Saúl ^b   Villalobos Valencia, Ricardo ^b   Ramírez Márquez, Marcelino ^c  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b HOSPITAL DE ONCOLOGÍA   (Mexico)

^c Hospital Cima Chihuahua   (Mexico)

Author keywords

Bevacizumab; Colorectal cancer

Indexed keywords

ANGIOPOIETIN 2; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PROTEIN P53; RAF PROTEIN;

BLEEDING; CANCER CHEMOTHERAPY; CANCER STAGING; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; MICROSATELLITE INSTABILITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; REVIEW; TUMOR SUPPRESSOR GENE; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS;

EID: 79959483635     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11590440-000000000-00000     Document Type: Review

References (56)

1. Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009 Nov-Dec; 59 (6): 366-78
2. Arnold CN, Goel A, Blum HE, et al. Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer 2005 Nov 15; 104 (10): 2035-47 (Pubitemid 41579948)
3. O'Connell JB,Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. JNatl Cancer Inst 2004 Oct 6; 96 (19): 1420-5 (Pubitemid 39429665)
4. Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993 Mar 20; 306 (6880): 752-5 (Pubitemid 23080053)
5. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000 Aug; 18 (16): 2938-47 (Pubitemid 30644117)
6. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000 Mar 25; 355 (9209): 1041-7 (Pubitemid 30162806)
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun 3; 350 (23): 2335-42 (Pubitemid 38702844)
8. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/ leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005 Jun 1; 23 (16): 3706-12
9. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan StudyGroup.NEngl JMed 2000 Sep 28; 343 (13): 905-14
10. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004 Jan 15; 22 (2): 229-37 (Pubitemid 41095086)
11. Libbutti SK, Saltz LB, Tepper JE. Colon cancer. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: principles & practice of oncology. 8th Ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2008: 1232-85
12. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite- instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003 Jul 17; 349 (3): 247-57 (Pubitemid 36859476)
13. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 2000 Jul; 124 (7): 979-94
14. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer [online]. Available from URL: physician-gls/PDF/colon. pdf [Accessed 2010 Apr 1]
15. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998 Mar 15; 58 (6): 1149-58 (Pubitemid 28183202)
16. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL study. J Natl Cancer Inst 1998 May 6; 90 (9): 675-84 (Pubitemid 28222141)
17. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009 Apr 2; 360 (14): 1408-17
18. European Medicines Agency. Vectibix: summary of product characteristics 2009 [online]. Available from URL: http:// www.ema.europa.eu/humandocs/PDFs/ EPAR/vectibix/H- 741-PI-en.pdf [Accessed 2010 Apr 12]
19. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008 Dec 10; 26 (35): 5705-12
20. Chua W, Kho PS, Moore MM, et al. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol. Epub 2010 Aug 16
21. De Roock W, Biesmans B, De Schutter J, et al. Clinical biomarkers in oncology: focus on colorectal cancer. Mol Diagn Ther 2009; 13 (2): 103-14
22. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006 Jan 10; 24 (2): 217-27 (Pubitemid 46622051)
23. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010 Jan 5; 102 (1): 8-18
24. Augustin HG, Koh GY, Thurston G, et al. Control of vascular morphogenesis and homeostasis through the angiopoietin- Tie system. Nat Rev Mol Cell Biol 2009 Mar; 10 (3): 165-77
25. Goede V, Coutelle O, Neuneier J, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumabcontaining therapy. Br J Cancer 2010 Oct 26; 103 (9): 1407-14
26. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010 Jan 20; 28 (3): 453-9
27. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005 Feb; 15 (1): 102-11 (Pubitemid 40127638)
28. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000 Sep 14; 407 (6801): 249-57
29. Verheul HM, Voest EE, Schlingemann RO. Are tumours angiogenesis- dependent? J Pathol 2004 Jan; 202 (1): 5-13
30. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999 Jun 18; 284 (5422): 1994-8 (Pubitemid 29309448)
31. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000 Apr; 156 (4): 1363-80 (Pubitemid 30660013)
32. Padera TP, Stoll BR, Tooredman JB, et al. Pathology: cancer cells compress intratumour vessels [abstract]. Nature 2004 Feb 19; 427 (6976): 695 (Pubitemid 38294577)
33. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002 Dec 19-26; 420 (6917): 860-7 (Pubitemid 36019639)
34. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997 Feb; 18 (1): 4-25 (Pubitemid 27076453)
35. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989 Dec 1; 8 (12): 3801-6 (Pubitemid 20016061)
36. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002 Nov 1; 20 (21): 4368-80 (Pubitemid 35266299)
37. Melder RJ, Koenig GC, Witwer BP, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996 Sep; 2 (9): 992-7 (Pubitemid 26306837)
38. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004 Aug; 25 (4): 581-611 (Pubitemid 39099316)
39. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004 May; 3 (5): 391-400 (Pubitemid 38618122)
40. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005 Jul 6; 97 (13): 981-9 (Pubitemid 41430564)
41. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007 Oct 20; 25 (30): 4779-86 (Pubitemid 350086481)
42. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008 Apr 20; 26 (12): 2013-9
43. Giantonio BJ, Catalano PJ, MeropolNJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 2007 Apr 20; 25 (12): 1539-44 (Pubitemid 46733080)
44. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecanrefractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007 Oct 10; 25 (29): 4557-61 (Pubitemid 350035312)
45. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)ASCO Annual Meeting Proceedings; 2008 May 30-Jun 3; Chicago (IL)
46. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)J Clin Oncol 2008 Nov 20; 26 (33): 5326-34
47. Van Cutsem E, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009 May; 20 Suppl. 4: 61-3
48. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008 Mar 22; 371 (9617): 1007-16 (Pubitemid 351392040)
49. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009 Jun; 20 (6): 985-92
50. Cunningham D, Kretzschmar A, Berry S, et al. Efficacy and safety of surgery with curative intent in patients treated with first-line bevacizumab for mCRC: first BEAT [abstract no. 445]. American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium; 2008 Jan 25-27; Orlando (FL)
51. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008 Apr 10; 26 (11): 1830-5
52. Okines A, Puerto OD, Cunningham D, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer first BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009 Oct 6; 101 (7): 1033-8
53. Zorzi D, Kishi Y, Maru DM, et al. Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastases [abstract no. 295]. American Society of Clinical Oncology 2009 Gastrointestinal Cancers Symposium; 2009 Jan 15-17; San Francisco (CA)
54. Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007 Jan; 12 (1): 38-50 (Pubitemid 46143501)
55. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006 Jan 20; 24 (3): 394-400 (Pubitemid 46630458)
56. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 2009 Dec 1; 27 (34): 5727-33